1. Home
  2. BMEA vs TUSK Comparison

BMEA vs TUSK Comparison

Compare BMEA & TUSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.40

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Logo Mammoth Energy Services Inc.

TUSK

Mammoth Energy Services Inc.

HOLD

Current Price

$3.35

Market Cap

127.7M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
TUSK
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oilfield Services/Equipment
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
127.7M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
BMEA
TUSK
Price
$1.40
$3.35
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$9.83
N/A
AVG Volume (30 Days)
1.2M
426.7K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
102.32
EPS
N/A
0.11
Revenue
N/A
$44,292,000.00
Revenue This Year
N/A
$383.90
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$30.09
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.72
52 Week High
$3.07
$3.60

Technical Indicators

Market Signals
Indicator
BMEA
TUSK
Relative Strength Index (RSI) 45.33 63.36
Support Level $1.23 $2.09
Resistance Level $1.45 $3.54
Average True Range (ATR) 0.10 0.27
MACD 0.00 0.00
Stochastic Oscillator 47.57 60.42

Price Performance

Historical Comparison
BMEA
TUSK

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About TUSK Mammoth Energy Services Inc.

Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.

Share on Social Networks: